
    
      This was a randomized single-dose, open-label and active-controlled study which was carried
      out in 96 primary gout patients. Subjects and doctors have no access to randomization
      sequence which is determined by the primary investigator.All patients received an open-label
      febuxostat 40mg daily during the whole study. Healthy control were 32 age-matched men from
      volunteers in the medical health center.Two primary end points included pain intensity
      measurement which was recorded at each visit and subsequently acute flare times which was
      recorded at home and reported to investigator.
    
  